The gut microbiota has emerged as a critical immune–metabolic interface, orchestrating a complex network of interactions that extend well beyond digestion. This highly diverse community of bacteria, viruses, archaea, and eukaryotic microbes modulates host immunometabolism, metabolic reprogramming, and systemic inflammatory responses, thereby shaping human health and disease trajectories. Dysbiosis, or disruption of microbial homeostasis, has been implicated in inflammatory bowel disease, cardiometabolic disorders, neurodegeneration, dermatological conditions, and tumorigenesis. Through the biosynthesis of short-chain fatty acids (SCFAs), bile acid derivatives, tryptophan metabolites, and microbial-derived indoles, the gut microbiota regulates epigenetic programming, barrier integrity, and host–microbe cross-talk, thereby influencing disease onset and progression. In oncology, specific microbial taxa and oncomicrobiotics (cancer-modulating microbes) are increasingly recognized as key determinants of immune checkpoint inhibitor (ICI) responsiveness, chemotherapeutic efficacy, and resistance mechanisms. Microbiota-targeted strategies such as fecal microbiota transplantation (FMT), precision probiotics, prebiotics, synbiotics, and engineered microbial consortia are being explored to recalibrate microbial networks and enhance therapeutic outcomes. At the systems level, the integration of multi-omics platforms (metagenomics, transcriptomics, proteomics, and metabolomics) combined with network analysis and machine learning-based predictive modeling is advancing personalized medicine by linking microbial signatures to clinical phenotypes. Despite remarkable progress, challenges remain, including the standardization of microbiome therapeutics, longitudinal monitoring of host–microbe interactions, and the establishment of robust ethical and regulatory frameworks for clinical translation. Future directions should prioritize understanding the causal mechanisms of microbial metabolites in immunometabolic regulation, exploring microbial niche engineering, and developing precision microbiome editing technologies (CRISPR, synthetic biology).

The gut microbiota has emerged as a critical immune-metabolic interface, orchestrating a complex network of interactions that extend well beyond digestion. This highly diverse community of bacteria, viruses, archaea, and eukaryotic microbes modulates host immunometabolism, metabolic reprogramming, and systemic inflammatory responses, thereby shaping human health and disease trajectories. Dysbiosis, or disruption of microbial homeostasis, has been implicated in inflammatory bowel disease, cardiometabolic disorders, neurodegeneration, dermatological conditions, and tumorigenesis. Through the biosynthesis of short-chain fatty acids (SCFAs), bile acid derivatives, tryptophan metabolites, and microbial-derived indoles, the gut microbiota regulates epigenetic programming, barrier integrity, and host–microbe cross-talk, thereby influencing disease onset and progression. In oncology, specific microbial taxa and oncomicrobiotics (cancer-modulating microbes) are increasingly recognized as key determinants of immune checkpoint inhibitor (ICI) responsiveness, chemotherapeutic efficacy, and resistance mechanisms. Microbiota-targeted strategies such as fecal microbiota transplantation (FMT), precision probiotics, prebiotics, synbiotics, and engineered microbial consortia are being explored to recalibrate microbial networks and enhance therapeutic outcomes. At the systems level, the integration of multi-omics platforms (metagenomics, metabolomics, transcriptomics, and proteomics) combined with network analysis and machine learning-based predictive modeling is advancing personalized medicine by linking microbial signatures to clinical phenotypes. Despite remarkable progress, challenges remain, including the standardization of microbiome therapeutics, longitudinal monitoring of host–microbe interactions, and the establishment of robust ethical and regulatory frameworks for clinical translation. Future directions should prioritize understanding the causal mechanisms of microbial metabolites in immunometabolic regulation, exploring microbial niche engineering, and developing precision microbiome editing technologies (CRISPR, synthetic biology).

Highly Pathogenic Avian Influenza (HPAI) viruses, particularly IAV (H5N1), continue to pose a major global threat due to their widespread circulation and high mortality rates in birds. Management of HPAI is complicated by challenges in conserving migratory bird populations, sustaining poultry production, and uncertainties in disease dynamics. Structured decision-making frameworks, such as those based on the PrOACT model, are recommended to improve outbreak response and guide critical actions, especially when HPAI virus (HPAIV) detections occur in sensitive areas like wildlife refuges. Surveillance data from late 2024 to early 2025 show persistent HPAI activity, with 743 detections across 22 European countries and beyond, and notable outbreaks in poultry in nations like Hungary, Iceland, and the UK. The proximity of poultry farms to water sources increases environmental contamination risks. Meanwhile, HPAI A(IAV (H5N1)) and other H5Nx viruses have been detected in a wide range of mammalian species globally, raising concerns about mammalian adaptation due to mutations like E627K and D701N in the PB2 protein. Human infections with IAV (H5N1) have also been reported, with recent cases in North America highlighting zoonotic transmission risks. Molecular studies emphasize the importance of monitoring genetic variations associated with increased virulence and antiviral resistance. Preventive strategies focus on biosafety, personal protective measures, and vaccine development for both avian and human populations. Ongoing genetic characterization and vigilant surveillance remain critical to managing the evolving threat posed by HPAI viruses.

The ongoing panzootic of the highly pathogenic avian influenza (HPAI) H5N1 virus, dominated by clade 2.3.4.4b, constitutes a significant global threat to wildlife, animal health, and public health. Once characterized by sporadic outbreaks, H5N1 has evolved into a sustained, year-round infection with an expanded host range that now includes numerous mammalian species. Its high pathogenicity is primarily driven by the acquisition of a polybasic haemagglutinin cleavage site, enabling systemic viral spread, alongside emerging endothelial and neurotropic properties that contribute to severe disease and high mortality in mammals. Although zoonotic transmission remains limited, H5N1 continues to accumulate mutations associated with mammalian adaptation, particularly within the haemagglutinin and polymerase complex. Notably, recent outbreaks in U.S. dairy cattle highlight the emergence of novel mammalian reservoirs with increased human exposure risk. Concurrently, vaccination strategies are advancing beyond traditional adjuvanted inactivated vaccines toward next-generation platforms, including mRNA and virus-like particle vaccines, designed for rapid deployment and broader immune protection. However, ongoing viral evolution, constrained vaccine availability, and gaps in coordinated surveillance underscore the urgent need for an integrated One Health approach to reduce panzootic risk.

Background: Microbial adaptation is a fundamental process by which microorganisms dynamically adjust to changes in their environment. Microbial adaptation includes both short-term and long-term mechanisms that enable microorganisms to survive and thrive in changing environmental conditions. Microbial adaptation processes can result in evolutionary changes that provide sustainable advantages. These processes allow microbes to develop traits such as antibiotic resistance and enhanced biofilm formation, ensuring their survival and proliferation in diverse environments. Despite substantial progress, there remains a critical gap in the literature regarding a comprehensive synthesis of microbial adaptation mechanisms and their implications for enhancing food safety and ensuring the sustainable production of industrially valuable biochemicals. Objectives: This document seeks to provide a comprehensive overview of recent advancements in understanding resistance mechanisms to various environmental stresses for enhancement of food safety, including oxidative stress, hyperosmotic stress, thermal stress, acid stress, and organic solvent stress. In addition, the study examines the applications of stress-resistant mechanisms in producing diverse biomolecules and valuable chemicals. Finally, the manuscript offers a discuss prospects for identifying stress-resistant mechanisms through systems biology and further engineering these elements using synthetic biology to enhance productivity. Methods: The literature review sought to cover the most important aspects of stress-resistant mechanisms in the adaptation processes of microorganisms and their role in food safety and sustainable production of valuable biochemicals. This review was not limited to a specific time period, geographic or language scope, or publication type, although preference was given to peer-reviewed open access sources. Results: Researchers have found that adaptive responses of pathogens to factors such as changes in temperature, disinfectants, and storage conditions can pose significant challenges to traditional food safety practices. At the same time, microbial adaptation is an integral part of ecosystem functioning, profoundly influencing processes such as nutrient cycling, decomposition, and soil fertility. The soil microbial community plays a vital role in the safety of cultivated produce, as it acts as a key indicator of soil ecological status and the effectiveness of remediation of contaminated soils. Microorganisms serve as climate change signalling indicators, actively contributing to climate regulation. Higher temperatures, precipitation variations, and higher CO2 concentrations can increase microbial growth rates, potentially increasing the prevalence of pathogens in both plant and animal foods. Natural and synthetic microbial stressors are effective mechanisms for food quality and safety management. Adaptation to chemical stress provides microbial resistance to polluted environments and industrial processes, with implications for bioremediation, public health, and environmental sustainability. Conclusion: Microbial adaptation results from the interplay of environmental stressors, genetic variation, ecological interactions, and anthropogenic impacts that determine the resilience, diversity, and adaptive capacity of microbial communities in a variety of habitats and ecosystems. By manipulating these adaptive pathways through combined or sequential stressors (e.g., low heat and low pH), food technologists can disrupt microbial survival without compromising nutritional value. As the environmental stressor landscape continues to rapidly evolve, driven by anthropogenic activities, climate shifts, and emerging environmental disturbances, monitoring how microorganisms acclimate and evolve in response to these dynamic forces remains important.